Clinical Trials Logo

Clinical Trial Summary

A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03669588
Study type Interventional
Source argenx
Contact
Status Completed
Phase Phase 3
Start date August 22, 2018
Completion date April 6, 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05514873 - An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors Phase 3
Completed NCT04124965 - A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Phase 3
Recruiting NCT04833894 - Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis Phase 2/Phase 3
Recruiting NCT04963270 - A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis Phase 3
Active, not recruiting NCT02950155 - A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis Phase 3
Completed NCT03315130 - Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis Phase 2
Recruiting NCT05556096 - Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis Phase 3
Completed NCT03920293 - Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis Phase 3
Not yet recruiting NCT06149559 - A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis Phase 2/Phase 3
Recruiting NCT06055959 - A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis Phase 2/Phase 3
Completed NCT03770403 - A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. Phase 3
Completed NCT03971422 - A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Phase 3
Recruiting NCT05403541 - Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis Phase 3
Recruiting NCT05644561 - Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) Phase 3
Completed NCT00515450 - Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis Phase 3
Active, not recruiting NCT06064695 - Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis N/A
Withdrawn NCT04982289 - Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis Phase 2
Completed NCT04735432 - Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis Phase 3
Completed NCT04650854 - A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis Phase 3
Not yet recruiting NCT06193889 - A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis Phase 2